Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO1997018332) REGULATION OF CANCER-CAUSING TYROSINE KINASES BY POTASSIUM ION CONDUCTANCE
Latest bibliographic data on file with the International Bureau

Pub. No.: WO/1997/018332 International Application No.: PCT/US1996/018304
Publication Date: 22.05.1997 International Filing Date: 12.11.1996
Chapter 2 Demand Filed: 14.05.1997
IPC:
A61K 31/4184 (2006.01) ,A61K 31/506 (2006.01) ,A61K 38/00 (2006.01) ,A61K 38/15 (2006.01) ,A61K 48/00 (2006.01) ,C07K 14/705 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
41
having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
4164
1,3-Diazoles
4184
condensed with carbocyclic rings, e.g. benzimidazoles
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
495
having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
505
Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
506
not condensed and containing further heterocyclic rings
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38
Medicinal preparations containing peptides
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38
Medicinal preparations containing peptides
04
Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
15
Depsipeptides; Derivatives thereof
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
48
Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
14
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435
from animals; from humans
705
Receptors; Cell surface antigens; Cell surface determinants
Applicants:
BRANDEIS UNIVERSITY [US/US]; 415 South Street Waltham, MA 02254-9110, US
Inventors:
HOLMES, Todd, C.; US
LEVITAN, Irwin, B.; US
Agent:
BROOK, David, E. ; Hamilton, Brook, Smith & Reynolds Two Militia Drive Lexington, MA 02173, US
Priority Data:
08/556,50413.11.1995US
Title (EN) REGULATION OF CANCER-CAUSING TYROSINE KINASES BY POTASSIUM ION CONDUCTANCE
(FR) REGULATION DES TYROSINE-KINASES CANCEROGENES PAR CONDUCTANCE EN IONS POTASSIUM
Abstract:
(EN) The present invention provides a method for treating protein tyrosine kinase-mediated conditions by administering to a mammal an agent that increases cell membrane potassium ion conductance. Protein tyrosine kinase-mediated conditions include psoriasis, atherosclerosis and cancers. In one embodiment the agent is a compound that activates endogenous potassium ion channels. In a second embodiment, the agent is a compound which reacts with potassium ion to form a membrane-permeant complex. In a preferred embodiment, the agent is a potassium ion channel protein administered via incorporation of a DNA molecule encoding the protein into the cellular genome. The present invention also includes a pharmaceutical composition comprising a vector containing a gene encoding a potassium ion channel protein in a form suitable for administration to a mammal. In yet another embodiment, the present invention includes a method or assay for determining the activity of compounds which are potential potassium ion channel activators or inactivators. The present invention also comprises a method for determining the virulence of cancerous cells by measuring the potassium ion conductance of the cells.
(FR) La présente invention concerne une méthode pour traiter des pathologies induites par la protéine tyrosine-kinase, consistant à administrer à un mammifère un agent augmentant la conductance en ions potassium des membranes cellulaires. Ces pathologies induites par la tyrosine-kinase englobent le psoriasis, l'athérosclérose et les cancers. Dans un mode de réalisation, l'agent est un composé activant les vannes endogènes à ions potassium. Dans un deuxième mode de réalisation, l'agent est un composé réagissant avec l'ion potassium pour former un complexe membrane-perméant. Dans un mode préféré de réalisation, l'agent est une protéine des vannes à ions potassium administrée par l'intermédiaire de l'incorporation d'une molécule d'ADN codant pour cette protéine dans le génome cellulaire. La présente invention se rapporte également à une composition pharmaceutique comprenant un vecteur contenant, dans une forme convenant à l'administration à un mammifère, un gène codant pour une protéine des vannes à ions potassium. Dans encore une autre forme de réalisation, la présente invention concerne une méthode ou un dosage pour déterminer l'activité de composés qui sont de puissants activateurs ou inactivateurs des vannes à ions potassium. La présente invention a trait également à une méthode pour déterminer la virulence des cellules cancéreuses en mesurant la conductance en ions potassium des cellules.
Designated States: AU, BA, CA, CU, JP, LC
European Patent Office (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE)
Publication Language: English (EN)
Filing Language: English (EN)
Also published as:
AU1996077338